Plasma fractionation market expected to reach $65.98 billion by 2032
The global Plasma Fractionation Market was valued at USD 34.84 billion in 2024 and is projected to reach USD 65.98 billion by 2032, with a CAGR of 8.36% during 2025-2032. The market growth is driven by increasing demand for plasma-derived therapy in treating immune disorders, chronic diseases, and neurological conditions.
In the U.S., the plasma fractionation market was estimated at USD 13.69 billion in 2024 and is expected to reach USD 25.26 billion by 2032, growing at a CAGR of 8.01%. North America dominates the market due to its established infrastructure, regulatory framework, and demand for plasma-derived therapies.
The Immunoglobulins segment accounted for 64.1% of the total plasma fractionation market in 2024, with applications in immune disorders and neurological conditions. Chromatography was the dominant method in 2024, with a 35.60% market share, offering efficient separation and purification of plasma proteins.
The neurology segment held the largest market share for immunoglobulins in 2024, at 29.8%, due to the established use of immunoglobulins in treating neurological disorders. North America held the largest market share in 2024, while Asia Pacific is expected to be a significant growing market due to increased healthcare expenditure and rising demand for plasma-derived therapies.
Read more at GlobeNewswire: Plasma Fractionation Market Size to Reach USD 65.98 Billion